Syra Health Corp. Class A Common Stock Q1 FY2024 earnings call

Management Statement and Operational Highlights

• Revenues in Q1 2024 increased 47% with growth across majority business units.
• Multiple contract wins translating to 2024 revenues, confident in $9M to $11M guidance for 2024.
• Population health and healthcare workforce to drive 2024 growth, with other units also growing.
• Operating in 19 states, diversified revenues beyond legacy healthcare workflows.
• Launched Government Solutions in late 2023, expanding into federal space.
• Key technology products include Syrenity, SyraBot, Care Plus; SyraBot deployed to a managed care organization in Indiana.
• Focus on research and development, e.g., Syrenity research study approved by Pearl Institutional Review Board.

Segment Performance

• Population Health: Revenues in the first quarter of 2024 were $232,000, up from $74,000 in the first quarter of 2023, a growth of over 213%. Contributed 13.65% of total revenues in Q1 2024.
• Healthcare Workflow: Grew 28% in Q1 2024, with revenue of $1.4 million.
• Digital Health: Generated $92,000 in Q1 2024, driven by SyraBot launched in Q3 2023, contributing 5.41% of total revenues in Q1 2024.
• Behavioral and Mental Health: Combined with Health Education had revenues of $11,000 in Q1 2024, up from $3,000 in Q1 2023.
• Health Education: Continues to win new and repeat business, e.g., awarded contracts in Arizona and Kansas.
• Government Solutions: Expanded into federal government space, with ongoing engagement and growing pipeline.

Guidance

• Confident in 2024 revenue guidance of $9 million to $11 million, based on contracts in hand and pending implementation.
• Majority of revenues expected in the last half of 2024 due to customer implementation cycles.

Risks

• No specific risks explicitly discussed in the transcript, but general risks related to contract execution, market competition, and regulatory changes could be implied.

Question and Answer

Q: Can you speak about the timing of these revenues? Are they mostly back half weighted?

A: We’re happy to reiterate our financial guidance over $9 million to $11 million for 2024, which is about 64% to 100% increase over our 2023 revenues. We do expect the majority of those revenues to be reflected in the last half of this year due to the implementation cycle of our customers.

Q: What do you attribute this success to?

A: Syra Health has an experienced team of scientifically driven healthcare and technology professionals and their dedication to excellence, illustrated by our comprehensive suite of innovative services and technology solutions. Our success is evident in the number of contracts we have successfully secured and the continued revenue growth.

Q: What is driving the growth in population health?

A: Yes, we are skilled at conducting gap analysis to determine what our customers are seeking, driven by an accomplished team of epidemiologists and research scientists. We are experiencing strong demand for our epidemiology services, shaping the strategic framework of organizations for improving healthcare, and evaluating state and county programs to improve the health outcomes of entire communities.